v3.26.3
SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Fair Value Measurements
  a. Fair Value Measurements

 

Cash and cash equivalents, restricted cash, prepaid expenses and other assets, trade payables and accrued expenses and other liabilities, are stated at their carrying value which approximates their fair value due to the short time to the expected receipt or payment.

 

The following tables present information about the Company’s financial assets and liabilities that are measured in fair value on a recurring basis as of September 30, 2026 and December 31, 2025 (in thousands):

 

          Fair value measurements as of  
Description  

Fair Value

Hierarchy

   

September 30,

2026

   

December 31,

2025

 
                   
Financial Liabilities:                        
Contingent consideration – Skelable acquisition     Level 3       195       -  
Derivative liability     Level 3       2,235       1,366  
Warrants liability     Level 3       1,988       -  
Total liabilities measured at fair value           $ 4,418     $ 1,366  

 

On June 30, 2026, the convertible loan, the pre-funded warrants and the warrants agreements that were issued with the New Notes were modified. Prior to the execution of the (i) Amended and Restated Senior Secured Convertible Note, (ii) Amended and Restated Common Warrant and (iii) Amended and Restated Pre-Funded Warrant (collectively, the “Amended and Restated Note and Warrant Documents”), the Company remeasured the derivative liability and warrant liability to fair value. Following the execution of the Amended and Restated Note and Warrant Documents, the derivative liability, warrant liability and pre-funded warrant liability associated with the instruments amended on June 30, 2026 were no longer required to be classified as liabilities under ASC 815-40, “Derivatives and Hedging.” As such, the Company reclassified these liabilities to equity as of the modification date.

 

On July 6, 2026, the Company issued $5.6 million of senior secured convertible notes (the “July Notes”) and accompanying freestanding warrants. The estimated fair value of the derivative liability and warrant liability was determined using the Black-Scholes option-pricing model, which is a Level 3 fair value measurement. The model requires the use of several key assumptions, including the stock price, exercise price, expected term, expected volatility, risk-free interest rate, and expected dividend yield, which represent significant unobservable Level 3 inputs.

 

The following table provides the inputs used for Level 3 fair value measurements of derivative liability:

 

   

September 30,

2026

   

December 31,

2025

 
Stock price   $ 6.60     $ 6.96  
Term (in years)     2.76       0.37  
Volatility     79.89 %     87.91%-93.12 %
Risk-free rate     5.01 %     3.65 %
Dividend yield     -       -  

 

The following table provides the inputs used for Level 3 fair value measurements of warrant liability:

 

   

September 30,

2026

   

December 31,

2025

 
Stock price   $ 6.60     $ -  
Term (in years)     4.77       -  
Volatility     69.33 %     -  
Risk-free rate     5.18 %     -  
Dividend yield     -       -  

 

The following table provides the inputs used for Level 3 fair value measurements of contingent consideration:

 

   

September 30,

2026

   

December 31,

2025

 
Term (in years)     1.13-1.63       -  
Probability of achievement     75.0%-90.0 %     -  
Risk-free rate     4.22 %     -  

 

Derivative liability at fair value

 

The following table summarizes the derivative liability activity as of September 30, 2026 (in thousands):

 

    Derivative liability  
Balance December 31, 2025   $ 1,366  
Issuance of derivative liability     2,478  
Change in fair value     (647 )
Balance March 31, 2026   $ 3,197  
Change in fair value     912  

Reclassification to equity upon modification of financing instruments

    (4,108 )
Balance June 30, 2026   $ -  
Issuance of derivative liability     2,972  
Change in fair value     (737 )
Balance September 30, 2026   $ 2,235  

 

Warrant Liabilities at Fair Value

 

The following table summarizes the warrant liability activity as of September 30, 2026 (in thousands):

 

    Warrant liability  
Balance June 30, 2026   $ -  
Issuance of warrant liability     2,598  
Change in fair value     (610 )
Balance September 30, 2026   $ 1,988  
Convertible Promissory Notes
  b. Convertible Promissory Notes

 

The Company applies ASC 470-20, “Debt with Conversion and Other Options” (“ASC 470-20”). In accordance with ASC 470-20 the Company first allocates the proceeds to freestanding liability instrument that are measured at fair value at each reporting date, based on their fair value. The remaining proceeds are allocated between the convertible debt and any bifurcated embedded derivatives.

 

In accordance with ASC 815 “Derivatives and Hedging” (“ASC 815”), the Company bifurcates embedded derivatives for the conversion option that require bifurcation and accounts for it separately from the convertible debt.

 

The Company applies ASC 815, to all features related to convertible debt. When features meet the definition of a derivative that do not qualify for any scope exceptions within ASC 815, they are required to be accounted for separately from the debt instrument and recorded as derivative instrument liabilities. The fair value assigned to the embedded derivative instruments is marked to market in each reporting period. The Company has recorded embedded derivative liabilities related to the convertible promissory notes. Liability classified bifurcated embedded derivatives are presented in the same line item with the related debt host liability.

 

For further information regarding the convertible promissory notes, see Note 9.

Revenue Recognition
  c. Revenue Recognition

 

The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to clinics and rehabilitation centers, professional and college sports teams, private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), and distributors.

 

Disaggregation of Revenues (in thousands):

 

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
Sale of products   $ 4,434     $ 4,989     $ 12,838     $ 13,276  
Lease of products     366       474       1,158       1,362  
Service and warranties     628       732       1,978       2,315  
Total Revenue   $ 5,428     $ 6,195     $ 15,974     $ 16,953  

 

Product revenue

 

The Company offers products including: (1) ReWalk Personal, (2) ReWalk Rehabilitation, (3) AlterG Anti-Gravity systems, and (4) MyoCycle. The Company previously commercialized ReStore but is no longer actively commercializing that product.

 

Revenue from products sold to rehabilitation facilities and end users is recognized at a point in time once the customer has obtained control of the products usually upon delivery.

 

The Company generally does not grant a right of return for its products.

 

In connection with the Medicare reimbursement pathway for the ReWalk product, the Company estimates variable consideration, including implicit price concessions, and includes such amounts in the transaction price only to the extent that it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company reassesses variable consideration at each reporting period and, if necessary, adjusts its estimates to reflect the anticipated amounts to be collected based on information then available.

 

For contracts with Medicare, the Company determines the amount of variable consideration that should be included at the transaction price, using contractual agreements and historical reimbursement experience with Medicare. The Company applies constraint to the transaction price, such that revenue is recorded only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect revenue in the period such adjustments become known. During the three and nine months ended September 30, 2026, as a result of a change in estimate, the Company recognized increases in revenue of approximately $0.1 million and $0.4 million, respectively, due to the consideration ultimately received compared with the amounts previously estimated. 

 

Lease revenue

 

A portion of the Company’s sales of products to customers are made through lease arrangements which typically include AlterG Anti-Gravity systems. Revenue for the lease of AlterG Anti-Gravity systems is accounted for under ASC 842, “Leases”. AlterG Anti-Gravity systems provided to customers under lease arrangements are accounted for in accordance with ASC 842 as an operating lease. Revenues are recognized ratably over the lease term.

 

Service and warranties

 

The Company provides product assurance warranties for periods of 1 to 10 years (usually 2 years) that cover the compliance of the products with agreed-upon specifications. A provision is recorded for estimated warranty costs based on the Company's experience.

 

A warranty is considered an assurance type warranty if it provides the customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.

 

In certain contracts, the company also provides a service-type warranty. A service-type warranty is accounted for as a separate performance obligation, and revenue is recognized ratably over the service period as the customer consumes the benefit over the service term.

 

Contract balances (in thousands):

 

    September 30,     December 31,  
    2026     2025  
Trade receivable, net of credit losses   $ 7,649     $ 6,138  
Deferred revenues (1)   $ 2,284     $ 2,153  

 

  (1) During the three and nine months ended September 30, 2026, $220 and $931 thousand of the December 31, 2025 deferred revenues balance was recognized as revenues.

 

Deferred revenue is composed primarily of unearned revenue related to service type warranty obligations, multi-year services contracts, as well as other advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been recognized.

 

The Company’s unearned performance obligations as of September 30, 2026 and the estimated revenue expected to be recognized in the future amounts to $2.4 million, which will be fulfilled over one to five years.

Concentrations of Credit Risks
  d. Concentrations of Credit Risks:

 

The table below presents the concentration of credit risk for the Company’s current customers as of September 30, 2026, to which substantial sales were made:

 

    September 30,     December 31,  
    2026     2025  
Customer A     58 %     56 %

 

The allowance for credit losses is based on the Company’s assessment of the collectability of accounts. The Company regularly assesses collectability based on a combination of factors, including an assessment of the current customer’s aging balance, the nature and size of the customer, the financial condition of the customer. The Company does not have any off-balance sheet credit exposure related to its customers. As of September 30, 2026 and December 31, 2025 trade receivables are presented net of allowance for credit losses in the amount of $209 thousand and $192 thousand respectively.

Warranty provision
  e. Warranty provision

 

For assurance-type warranties, the Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.

 

    US Dollars in thousands  
Balance at December 31, 2025   $ 343  
Provision     482  
Usage     (403 )
Balance at September 30 2026   $ 422  
Basic and diluted net loss per ordinary share
  f. Basic and diluted net loss per ordinary share:

 

Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential ordinary shares and warrants outstanding would have been anti-dilutive.

 

As of September 30, 2026 and 2025, outstanding warrants, share options, restricted stock units (“RSUs”) and convertible notes convertible or exercisable into 6,814,785 and 759,666 ordinary shares, respectively, were excluded from the calculation of diluted loss per ordinary share because their effect would have been anti-dilutive.

Goodwill and acquired intangible assets
  g. Goodwill and acquired intangible assets

 

Goodwill has been recorded in the Company’s financial statements resulting from various business combinations. Goodwill represents the excess of the purchase price in a business combination over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed. Goodwill is subject to an annual impairment test.

 

The Company currently has one reporting unit.

 

ASC 350, Intangibles - Goodwill and Other (“ASC 350”) requires goodwill to be tested for impairment at least annually and, in certain circumstances, between annual tests. The accounting guidance gives the option to perform a qualitative assessment to determine whether further impairment testing is necessary. The qualitative assessment considers events and circumstances that might indicate that a reporting unit’s fair value is less than its carrying amount. If it is determined, as a result of the qualitative assessment, that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative test is performed. The Company elects to perform an annual impairment test of goodwill as of December 31 of each year, or more frequently if impairment indicators are present.

 

The Company concluded that no impairment of goodwill was identified for the nine months ended September 30, 2026. Refer to Note 5 for further details.

Impairment of Long-Lived Assets
  h. Impairment of Long-Lived Assets

 

The Company’s long-lived assets, including right-of-use (“ROU”) assets and identifiable intangible assets that are subject to amortization, are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Acquired In-Process Research and Development
  i. Acquired In-Process Research and Development

 

In an asset acquisition, the initial costs of rights to in-process research and development projects acquired are expensed as research and development in the consolidated statements of operations unless the in-process research and development has an alternative future use. In a business combination, the fair value of in-process research and development is capitalized as an indefinite-lived intangible asset, regardless of whether the in-process research and development asset has an alternative future use.

Restricted cash and Other long-term assets:
  j. Restricted cash and Other long-term assets:

 

Other long-term assets include long-term prepaid expenses and restricted cash deposits for offices and cars leasing based upon the term of the remaining restrictions.

New Accounting Pronouncements
  k. New Accounting Pronouncements 

 

Recently Implemented Accounting Pronouncements

 

In July 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2025-05, “Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses for Accounts Receivable and Contract Assets”, which provides a practical expedient when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). The practical expedient assumes that current conditions as of the balance sheet date do not change for the remaining life of the assets. The Company adopted this guidance on January 1, 2026 on a prospective basis, and elected the practical expedient provided by ASU 2025-05. Under this expedient, the Company assumes that economic conditions as of the balance sheet date remain unchanged for the remaining life of all current accounts receivable and current contract assets arising from transactions under ASC 606. The Company continues to estimate expected credit losses for non-current receivables and contract assets in accordance with ASC 326. The adoption did not have a material impact on its consolidated financial statements.

 

Recent Accounting Pronouncements Not Yet Adopted

 

  i. In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

 

  ii. In December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. The update provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. The amendments introduce two permitted approaches for asset-related grants: a deferred income approach or a cost accumulation approach. The guidance is effective for the Company beginning December 15, 2028, with early adoption permitted. The Company is currently evaluating the impact on its consolidated financial statements.

 

  iii. In December 2025, the FASB issued ASU 2025-11 to amend the guidance in Interim Reporting (Topic 270). The update provides clarifications intended to improve the consistency and usability of interim disclosure requirements, including a comprehensive listing of required interim disclosures and a new disclosure principle for reporting material events occurring after the most recent annual period. The amendments do not change the underlying objectives of interim reporting but are designed to enhance clarity in application. The guidance is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years. The Company is currently evaluating the impact on its consolidated financial statements disclosures.